All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Effect of age and renal impairment on the pharmacokinetics and safety of trimetazidine: An open-label multiple-dose study

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F20%3AN0000051" target="_blank" >RIV/00064190:_____/20:N0000051 - isvavai.cz</a>

  • Result on the web

    <a href="http://dx.doi.org/10.1002/ddr.21654" target="_blank" >http://dx.doi.org/10.1002/ddr.21654</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1002/ddr.21654" target="_blank" >10.1002/ddr.21654</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Effect of age and renal impairment on the pharmacokinetics and safety of trimetazidine: An open-label multiple-dose study

  • Original language description

    This study evaluated the effect of age and renal impairment on pharmacokinetics of trimetazidine (TMZ) in healthy elderly and renally impaired subjects and assess safety and tolerability. In this open-label, multi-dose study, 73 subjects were divided into six treatment groups: (1) 55-65 years; (2) 66-75 years; (3) >75 years (dosing for groups 1-3 [healthy]: B.D. for 4 days), (4) mild renally impaired (dosed B.D. for 8 days); (5) moderate renally impaired (dosed O.D. for 8 days); and (6) severe renally impaired-no dialysis (dosed once every 48 h for 8 days). Blood and urine samples were collected and analyzed. The geometric least squares mean ratios for; Group 2 and 1 of AUC((0-tau)ss)was 112.2 (90% CI; 92.0-136.8) andC(max,ss)was 109.9 (89.6-134.8), Group 3 and 1 of AUC((0-tau),ss)was 140.5 (115.9-170.3) andC(max,ss)was 137.8 (112.9-168.2), Group 4 and 1 of AUC((0-tau),ss)was 114.2 (90.3-144.4) andC(max,ss)was 120.8 (92.5-157.8), Group 5 and 1 of; AUC((0-tau),ss)was 213.0 (153.1-296.3) andC(max,ss)was 123.3 (92.2-164.7) and Group 6 and 1 of AUC((0-tau),ss)was 247.4 (197.8-309.6) andC(max,ss)was 95.6 (73.0-125.1). Significant increase in systemic exposure of TMZ was observed in subjects; over 75 year's age and renally impaired compared to healthy subjects. TMZ was safe and well-tolerated.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30104 - Pharmacology and pharmacy

Result continuities

  • Project

  • Continuities

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Others

  • Publication year

    2020

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    DRUG DEVELOPMENT RESEARCH

  • ISSN

    0272-4391

  • e-ISSN

    1098-2299

  • Volume of the periodical

    81

  • Issue of the periodical within the volume

    5

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    9

  • Pages from-to

    564-572

  • UT code for WoS article

    000554917000006

  • EID of the result in the Scopus database

    2-s2.0-85081012752